Medication Guide App

Clomipramine Side Effects

Not all side effects for clomipramine may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

For the Consumer

Applies to clomipramine: oral capsule, oral tablet

In addition to its needed effects, some unwanted effects may be caused by clomipramine. In the event that any of these side effects do occur, they may require medical attention.

You should check with your doctor immediately if any of these side effects occur when taking clomipramine:

More common
  • Bladder pain
  • bloody or cloudy urine
  • blurred vision
  • body aches or pain
  • burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
  • confusion
  • difficult, burning, or painful urination
  • dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
  • excessive muscle tone
  • fear or nervousness
  • feeling sad or empty
  • fever
  • hearing changes
  • irritability
  • lower back or side pain
  • muscle stiffness, tension, or tightness
  • poor concentration
  • rhythmic movement of muscles
  • shortness of breath or troubled breathing
  • sneezing
  • tightness of the chest or wheezing
  • unusual tiredness or weakness
  • voice changes
Less common
  • Anger that is hard to control
  • breast enlargement
  • burning while urinating
  • changes in vision
  • chills
  • decrease in the frequency of urination
  • difficulty in passing urine (dribbling)
  • difficulty in speaking
  • dry mouth
  • fast, irregular, pounding, or racing heartbeat or pulse
  • headache, severe and throbbing
  • hyperventilation
  • irregular heartbeats
  • irritability
  • nausea or vomiting
  • numbness, tingling, pain, or weakness in the hands or feet
  • pain during sexual intercourse
  • panic attacks
  • paranoia
  • rapidly changing moods
  • restlessness
  • shaking
  • swelling of the face, fingers, feet, or lower legs

Some of the side effects that can occur with clomipramine may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:

More common
  • Acid or sour stomach
  • blistering, crusting, irritation, itching, or reddening of the skin
  • change in taste
  • constipation
  • cracked, dry, or scaly skin
  • change in interest in sexual intercourse
  • diarrhea
  • dry skin
  • heartburn
  • hives or welts, skin rash
  • inability to have or keep an erection
  • increased interest in sexual intercourse
  • joint pain
  • pimples
  • redness of the face, neck, arms, and occasionally, upper chest
  • shakiness in the legs, arms, hands, or feet
  • stomach discomfort, upset, or pain
  • swelling
  • swollen joints
  • trembling or shaking of the hands or feet
Less common
  • Absent, missed, or irregular menstrual periods
  • breast pain
  • sores, ulcers, or white spots on the lips or tongue or inside the mouth

For Healthcare Professionals

Applies to clomipramine: oral capsule

Nervous system

Nervous system side effects including drowsiness, dizziness, sedation, and headache have been reported frequently. Anticholinergic effects have been reported frequently and include dry mouth, blurry vision, constipation, and urinary retention. Tremor, delirium, akathisia, a tardive dyskinesia- like syndrome, myoclonus, motor hyperactivity during sleep, sleep abnormalities, dystonic reactions, Tourettism, and seizures have also been reported.[Ref]

Where a primary reason for discontinuation could be identified, most patients discontinued because of nervous system complaints (5.4%), primarily somnolence.

One study has suggested that sedation may occur in 87% of treated patients.

The manufacturer reports that the cumulative incidence of seizures during premarketing testing averaged 0.64% at 90 days and 1.45% at 365 days.

Nearly all selective serotonin reuptake inhibitors, mixed serotonin/norepinephrine reuptake inhibitors, and tricyclic antidepressants cause sleep abnormalities to some extent. These antidepressants have marked dose-dependent effects on rapid eye movement (REM) sleep, causing reductions in the overall amount of REM sleep over the night and delays the first entry into REM sleep (increased REM sleep onset latency (ROL)), both in healthy subjects and depressed patients. The antidepressants that increase serotonin function appear to have the greatest effect on REM sleep. The reduction in REM sleep is greatest early in treatment, but gradually returns towards baseline during long-term therapy; however, ROL remains long. Following discontinuation of therapy the amount of REM sleep tends to rebound. Some of these drugs (i.e., bupropion, mirtazapine, nefazodone, trazodone, trimipramine) appear to have a modest or minimal effect on REM sleep.[Ref]


Cardiovascular side effects that have been associated with the use of tricyclic antidepressants have included orthostatic hypotension, tachycardia, QRS widening, other conduction abnormalities, malignant arrhythmias, and malignant hypertension.[Ref]

Both antiarrhythmic and proarrhythmic effects have been reported in association with tricyclic therapy.

One study of the cardiovascular effects of clomipramine in 26 depressed patients suggested that clomipramine may produce variable and complex cardiac effects. The authors concluded that the drug is "generally well tolerated but it does present some degree of risk for the heart".

Caution should be exercised if clomipramine must be used in patients with cardiovascular disease.[Ref]


Psychiatric side effects with use of this drug have included mania and hallucinations. Suicidal ideation, paradoxical aggressiveness, and mental status changes have also been reported with use of clomipramine and other tricyclic antidepressants.[Ref]


A study of 26,005 antidepressant users has reported 3.6 times more upper GI bleeding episodes with the use of SSRI's relative to the population who did not receive antidepressant medications. Upper gastrointestinal tract bleeding was observed in 2.3 times more frequently in patients receiving clomipramine.

Where a primary reason for discontinuation could be identified, the second most frequent reason for discontinuation was digestive system complaints (1.3%), primarily nausea and vomiting.[Ref]

Gastrointestinal side effects have included nausea, vomiting, dry mouth, and constipation.[Ref]


General side effects including increased appetite and weight gain have been associated with the use of clomipramine.[Ref]


Other side effects including withdrawal reactions involving both rebound worsening of preexisting psychiatric conditions and physiologic symptoms have been reported. Abrupt discontinuation may result in symptoms of withdrawal (such as nausea, headache, malaise, irritability and generalized CNS stimulation). Specific physiologic withdrawal symptoms may include nervousness, anxiety, restlessness, akathisia, nausea, malaise, sweating, salivation and seizures. Tachycardia has also been reported.[Ref]

In one retrospective chart review of 352 patients who were supervised during tapering and discontinuation from serotonin reuptake inhibitor therapy, dizziness, lethargy, paresthesia, nausea, vivid dreams, irritability, and lowered mood were the most common symptoms reported. Patients with at least on qualitatively new symptom were defined in the clomipramine group at a rate of 30.8%.[Ref]


Genitourinary side effects have been reported frequently and have included sexual dysfunction (involving anorgasmia, impotence and decreased libido). Urinary retention has also been reported.[Ref]

Decreased nocturnal penile tumescence and delayed ejaculation have been reported.

One report has suggested that cyproheptadine may be beneficial in the treatment of clomipramine- induced anorgasmia.

Cases of spontaneous orgasm associated with yawning and clomipramine therapy have been reported.[Ref]


Hematologic side effects have been rare and have included agranulocytosis and pancytopenia.[Ref]


Endocrine side effects including hyponatremia (in association with the syndrome of inappropriate secretion of antidiuretic hormone) have been reported rarely. Hyperprolactinemia, galactorrhea and secondary amenorrhea have also been reported. A case of pancreatitis associated with clomipramine overdose has been reported.[Ref]

Following the ingestion of 750 mg to 1,500 mg of clomipramine, a 48 year old female patient developed acute chemical pancreatitis and subsequent abdominal ileus. Serum lipase levels were elevated to 2,546 international units at one point, with a concomitant serum amylase of 112 international units. Two weeks after discontinuing clomipramine and resting the patient's gastrointestinal tract, the ileus and pancreatitis had resolved.[Ref]


Hepatic side effects have been rare and have included elevated liver function tests and drug-induced hepatitis.[Ref]


Dermatologic side effects have included sweating (common) and drug eruptions, photosensitivity, and contact allergy (rare).[Ref]


Other side effects including neuroleptic malignant syndrome have been reported. One case of neuroleptic malignant syndrome in association with clomipramine (20 mg/day) has been reported. Symptoms including sweating, pyrexia, muscle rigidity, and urinary incontinence resolved with 48 hours after discontinuation of clomipramine and recurred upon rechallenge.[Ref]


Metabolic side effects including dyslipidemia have been reported. Dyslipidemia (i.e., hypercholesterolemia, hypertriglyceridemia) was reported in a patient receiving clomipramine 150 mg daily. A case of clomipramine-induced diabetes has also been reported.[Ref]


1. Kotler M, Iancu I, Kindler S, Lefkifker E, Zohar J "Clomipramine-induced tourettism in obsessive-compulsive disorder: clinical and theoretical implications." Clin Neuropharmacol 17 (1994): 338-43

2. Flechter S, Rabey JM, Regev I, Borenstein N, Vardi J "Convulsive attacks due to antidepressant drug overdoses: case reports and discussion." Gen Hosp Psychiatry 5 (1983): 217-21

3. Jenike MA, Baer L, Greist JH "Clomipramine versus fluoxetine in obsessive-compulsive disorder: a retrospective comparison of side effects and efficacy." J Clin Psychopharmacol 10 (1990): 122-4

4. Sandyk R "Persistent akathisia associated with early dyskinesia." Postgrad Med J 60 (1984): 916

5. Robinson ML "Epileptic fit after clomipramine." Br J Psychiatry 132 (1978): 525-6

6. "Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals, Summit, NJ.

7. Myers BA, Klerman GL, Hartmann E "Nocturnal cataclysms with myoclonus: a new side effect of clomipramine." Am J Psychiatry 143 (1986): 1490-1

8. Canomunoz JL, Montejoiglesias ML, Yanezsaez RM, Galvezborrero IM "Possible serotonin syndrome following the combined administration of clomipramine and alprazolam." J Clin Psychiatry 56 (1995): 122

9. Bental E, Lavie P, Sharf B "Severe hypermotility during sleep in treatment of cataplexy with clomipramine." Isr J Med Sci 15 (1979): 607-9

10. Pascual J, Combarros O, Berciano J "Partial status epilepticus following single low dose of chlorimipramine in a patient on MAO-inhibitor treatment." Clin Neuropharmacol 10 (1987): 565-7

11. Guillibert E, Pelicier Y, Archambault JC, Chabannes JP, Clerc G, Desvilles M, Guibert M, Pagot R, Poisat JL, Thobie Y "A double-blind, multicentre study of paroxetine versus clomipramine in depressed elderly patients." Acta Psychiatr Scand Suppl 350 (1989): 132-4

12. Gersten SP "Tardive dyskinesia-like syndromes with clomipramine ." Am J Psychiatry 150 (1993): 165-6

13. Feinberg M "Clomipramine for obsessive-compulsive disorder." Am Fam Physician 43 (1991): 1735-8

14. Wilson S, Argyropoulos S "Antidepressants and sleep: a qualitative review of the literature." Drugs 65 (2005): 927-47

15. Christensen P, Thomsen HY, Pedersen OL, et al "Cardiovascular effects of amitriptyline in the treatment of elderly depressed patients." Psychopharmacology (Berl) 87 (1985): 212-5

16. Robinson DS, Nies A, Corcella J, Cooper TB, Spencer C, Kefover R "Cardiovascular effects of phenelzine and amitriptyline in depressed outpatients." J Clin Psychiatry 43 (1982): 8-15

17. Dunn FG "Malignant hypertension associated with use of amitriptyline hydrochloride." South Med J 75 (1982): 1124-5

18. Veith RC, Bloom V, Bielski R, Friedel RO "ECG effects of comparable plasma concentrations of desipramine and amitriptyline." J Clin Psychopharmacol 2 (1982): 394-8

19. Van Sweden B "Rebound antidepressant cardiac arrhythmia." Biol Psychiatry 24 (1988): 363-4

20. Faravelli C, Brat A, Marchetti G, Franchi F, Padeletti L, Michelucci A, Pastorino A "Cardiac effects of clomipramine treatment. ECG and left ventricular systolic time intervals." Neuropsychobiology 9 (1983): 113-8

21. van Kammen DP, van Scheyen JD, Murphy DL "Platelet monoamine oxidase activity and clomipramine-induced mania in unipolar depressed patients." Biol Psychiatry 15 (1980): 565-73

22. Cruz R "Clomipramine side effects." J Am Acad Child Adolesc Psychiatry 31 (1992): 1168-9

23. Harper G "Suicidality with clomipramine." J Am Acad Child Adolesc Psychiatry 31 (1992): 369-70

24. Vallada HP, Gentil V "Musical hallucinations triggered by clomipramine?" Br J Psychiatry 159 (1991): 888-9

25. Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH "Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study." Arch Intern Med 163 (2003): 59-64

26. Ananth J, Assalian P, Links PS "Intolerable side effects of clomipramine." J Clin Psychopharmacol 2 (1982): 215-6

27. Coupland NJ, Bell CJ, Potokar JP "Serotonin reuptake inhibitor withdrawal." J Clin Psychopharmacol 16 (1996): 356-62

28. Diamond BI, Borison RL, Katz R, DeVeaugh-Geiss J "Rebound withdrawal reactions due to clomipramine." Psychopharmacol Bull 25 (1989): 209-12

29. Pato MT, Zohar-Kadouch R, Zohar J, Murphy DL "Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder." Am J Psychiatry 145 (1988): 1521-5

30. McLean JD, Forsythe RG, Kapkin IA "Unusual side effects of clomipramine associated with yawning." Can J Psychiatry 28 (1983): 569-70

31. Riley AJ, Riley EJ "Cyproheptadine and antidepressant-induced anorgasmia." Br J Psychiatry 148 (1986): 217-8

32. Steiger A "Effects of clomipramine on sleep EEG and nocturnal penile tumescence: a long-term study in a healthy man." J Clin Psychopharmacol 8 (1988): 349-54

33. Quirk KC, Einarson TR "Sexual dysfunction and clomipramine." Can J Psychiatry 27 (1982): 228-31

34. Hermesh H, Aizenberg D, Weizman A, Lapidot M, Munitz H "Clomipramine-induced urinary dysfunction in an obsessive-compulsive adolescent." Drug Intell Clin Pharm 21 (1987): 877-9

35. Harrison W, Stewart J, McGrath PJ, Quitkin F "Unusual side effects of clomipramine associated with yawning." Can J Psychiatry 29 (1984): 546

36. Yassa R "Sexual disorders in the course of clomipramine treatment: a report of three cases." Can J Psychiatry 27 (1982): 148-9

37. Monteiro WO, Noshirvani HF, Marks IM, Lelliott PT "Anorgasmia from clomipramine in obsessive-compulsive disorder. A controlled trial." Br J Psychiatry 151 (1987): 107-12

38. Pigott TA, Pato MT, Bernstein SE, Grover GN, Hill JL, Tolliver TJ, Murphy DL "Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Behavioral and biological results." Arch Gen Psychiatry 47 (1990): 926-32

39. Klug B "Clomipramine in premature ejaculation." Med J Aust 141 (1984): 71

40. Souhami RL, Ashton CR, Lee-Potter JP "Agranulocytosis and systemic candidiasis following clomipramine therapy." Postgrad Med J 52 (1976): 472-4

41. Magni G, Urbani A, Silvestro A, Grassetto M "Clomipramine-induced pancytopenia." J Nerv Ment Dis 175 (1987): 309-10

42. Gravenor DS, Leclerc JR, Blake G "Tricyclic antidepressant agranulocytosis." Can J Psychiatry 31 (1986): 661

43. Hunt KA, Resnick MP "Clomipramine-induced agranulocytosis and its treatment with G-CSF." Am J Psychiatry 150 (1993): 522-3

44. Pledger DR, Mathew H "Hyponatraemia and clomipramine therapy." Br J Psychiatry 154 (1989): 263-4

45. Follenius M, Spiegel K, Gronfier C, Saini J, Brandenberger G "Clomipramine-induced sleep disturbance does not impair its prolactin-releasing action." J Endocrinol Invest 17 (1994): 417-23

46. Roberge RJ, Martin TG, Hodgman M, Benitez JG "Acute chemical pancreatitis associated with a tricyclic antidepressant (clomipramine) overdose." J Toxicol Clin Toxicol 32 (1994): 425-9

47. Garson M "Syndrome of dilutional hyponatraemia secondary to tricyclic antidepressant." Practitioner 222 (1979): 411-2

48. Fowlie S, Burton J "Hyperprolactinaemia and nonpuerperal lactation associated with clomipramine." Scott Med J 32 (1987): 52

49. Spigset O, hedenmalm K "Hyponatremia in relation to treatment with antidepressants: a survey of reports in the World Health Organization data base for spontaneous reporting of adverse drug reactions." Pharmacotherapy 17 (1997): 348-52

50. Anand VS "Clomipramine--induced galactorrhoea and amenorrhoea." Br J Psychiatry 147 (1985): 87-8

51. Larrey D, Rueff B, Pessayre D, Danan G, Algard M, Geneve J, Benhamou JP "Cross hepatotoxicity between tricyclic antidepressants." Gut 27 (1986): 726-7

52. Ljunggren B, Bojs G "A case of photosensitivity and contact allergy to systemic tricyclic drugs, with unusual features." Contact Dermatitis 24 (1991): 259-65

53. Tunca Z, Tunca MI, Dilsiz A, Bayol U, Hancioglu M "Clomipramine-induced pseudocyanotic pigmentation." Am J Psychiatry 146 (1989): 552-3

54. Haddow AM, Harris D, Wilson M, Logie H "Clomipramine induced neuroleptic malignant syndrome and pyrexia of unknown origin." BMJ 329 (2004): 1333-5

55. Holmes DT, Long P, Frohlich J "Dysbetalipoproteinemia and clomipramine." Am J Psychiatry 162 (2005): 1384-5

56. Mumoli N, Cei M "Clomipramine-induced diabetes." Ann Intern Med 149 (2008): 595-6

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.